Cost-effectiveness of intermediate or long-acting insulin versus Exenatide in type 2 diabetes mellitus patients not optimally controlled on dual oral diabetes medications. Pharm Pract (Granada) [Internet]. 2006 Oct. 26 [cited 2026 Apr. 16];4(3):129-33. Available from: https://pharmacypractice.org/index.php/pp/article/view/281